Behavioral Neuroscience – Products

The American scientist Ann Kennedy, PhD, assistant professor at Northwestern University, Chicago, USA has won the 2022 Eppendorf & Science Prize for Neurobiology for her work on the neural population dynamics that generate and maintain our emotions and behavioral drives.

Beckman Coulter Life Sciences announces that Suzanne Foster has been appointed as President of the company.

Beckman Coulter announces it will introduce new antipsychotic drug tests to laboratories and clinicians to address an unmet clinical need for 69 million people with serious mental conditions worldwide.

The American scientist Amber L. Alhadeff, Ph.D., Principal Investigator at the Monell Chemical Senses Center and the University of Pennsylvania, USA has won the 2021 Eppendorf & Science Prize for Neurobiology for her work on the gut-brain control of hunger circuits.

Wesana Health announced its commitment to fund an initial US $1.5 million to assess the viability of Multidisciplinary Association for Psychedelic Studies (MAPS) MDMA-assisted therapy to treat traumatic brain injury (TBI).

Alzheimer’s disease (AD) is the most common form of dementia, and it is also one of the most common neurodegenerative diseases. AD comes with memory impairments, and as a result many of the neurobehavioral studies done on AD involve the water maze test.

MEGIN is pleased to announce the acquisition of a TRIUX™ neo by The Centre For Cognitive Neuroimaging at the Institute for Neuroscience and Psychology at the University of Glasgow. This research facility will continue its role as the only MEG site in Scotland, continuously supporting neuroimaging related research.

A recent study describes for the first time the formation of room temperature therapeutic deep eutectic solvent (THEDES) of RIS, an antipsychotic drug that is used in the treatment of schizophrenia, mixed and manic states associated with bipolar disorder and irritability in children and adolescents with autism.

Woebot Health has announced that the Journal of Medical Internet Research (JMIR), has published the results of its latest study. The study is one of the first to explore substance use disorder interventions via mobile apps.

Havn Life Sciences Inc. a biotechnology company, announced it has signed a Memorandum of Agreement (“MOA”) with the international veterans organization, Heroic Hearts Project.